Phillip Capital
Revenue was in line with our estimates and was led by price/mix and flat volumes Gross margins rose 410bps yoy due to softer commodity costs/cost reduction initiatives Horlicks/Boost continued to gain market shares in respective categories...
More from GlaxoSmithKline Consumer Healthcare Ltd.
Recommended